PPARGC1A and liver cancer: Qian et al. [36] conducted an in-depth analysis of PPARGC1A using the Cancer Genome Atlas dataset to effectively assess the impact of PPARGC1A on the overall survival of liver cancer patients and discovered that PPARGC1A is a protective factor for liver cancer patients and ultimately better prevents and predicts liver cancer metastases through the development of a more effective high-throughput technology to identify metastasis inhibitors, which is supported by our Mendelian randomization study.